{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T19:01:33Z","timestamp":1780686093819,"version":"3.54.1"},"reference-count":34,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ARM"],"abstract":"<jats:p>Background: Highly effective CFTR modulation with Elexacaftor\/Tezacaftor\/Ivacaftor (ETI) markedly improves clinical outcomes in people with cystic fibrosis (CF). Data on its effects on physical activity, sleep, sinonasal symptoms, and parent-perceived outcomes in preschool-aged children are limited. Methods: In this prospective, observational, single-center cohort study, ten children with cystic fibrosis (aged 2\u20136 years) and at least one CFTR variant eligible for ETI were included. Data were collected using wrist-worn Garmin v\u00edvofit Junior 2 activity trackers and standardized questionnaires one month before ETI initiation and at 1, 3, 6, and 12 months after start of ETI. Outcomes included step count, minutes of moderate-to-vigorous physical activity, sleep parameters, sinonasal symptoms, and parental perceptions. Results: ETI was well tolerated. Sweat chloride levels decreased significantly. Physical activity improved at 3 and 6 months (step count and active minutes\/day; p &lt; 0.05) but declined to near-baseline levels at 12 months. Parental assessments of physical and sporting performance showed sustained improvement. Sleep duration remained stable, with no changes in deep or light sleep phases or nighttime awakenings. Sinonasal symptoms remained low. Discussion &amp; Conclusions: Preliminary findings of this exploratory pilot study show that improvement in physical activity after three and six months of ETI therapy might be attributable to seasonality, as therapy was started in winter months. No changes in sleep duration or sleep patterns are reassuring in this small cohort of young children with CF. ETI therapy was safe and well tolerated. Parental appraisal of their children\u2019s physical performance improved after start of ETI. Longitudinal, controlled studies involving larger cohorts are required to validate these findings and to account for potential confounding factors, such as age-dependent changes and individual and environmental factors such as seasonal variation.<\/jats:p>","DOI":"10.3390\/arm94030036","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T17:18:16Z","timestamp":1780679896000},"page":"36","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Highly Effective CFTR Modulator Therapy on Physical Activity, Sleep, and Sinonasal Symptoms in Preschool Children with Cystic Fibrosis: A Prospective Single-Center Pilot Study"],"prefix":"10.3390","volume":"94","author":[{"given":"Stella","family":"Schellhorn","sequence":"first","affiliation":[{"name":"Department of Pediatrics and Adolescent Medicin, Ulm University Medical Center, Ulm University, Eythstrasse 24, 89075 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Adolescent Medicin, Ulm University Medical Center, Ulm University, Eythstrasse 24, 89075 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ales","family":"Janda","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Adolescent Medicin, Ulm University Medical Center, Ulm University, Eythstrasse 24, 89075 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"G\u00fclke","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Adolescent Medicin, Ulm University Medical Center, Ulm University, Eythstrasse 24, 89075 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Toth","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Adolescent Medicin, Ulm University Medical Center, Ulm University, Eythstrasse 24, 89075 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2019-8101","authenticated-orcid":false,"given":"Dorit","family":"Fabricius","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Adolescent Medicin, Ulm University Medical Center, Ulm University, Eythstrasse 24, 89075 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7217-3312","authenticated-orcid":false,"given":"Sebastian F. N.","family":"Bode","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Adolescent Medicin, Ulm University Medical Center, Ulm University, Eythstrasse 24, 89075 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1002\/ppul.26954","article-title":"International disparities in diagnosis and treatment access for cystic fibrosis","volume":"59","author":"Guo","year":"2024","journal-title":"Pediatr. Pulmonol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"15010","DOI":"10.1038\/nrdp.2015.10","article-title":"Cystic fibrosis","volume":"1","author":"Ratjen","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s41030-025-00303-4","article-title":"Impact of CFTR Modulators on Longitudinal Cystic Fibrosis Survival and Mortality: Review and Secondary Analysis","volume":"11","author":"Rubin","year":"2025","journal-title":"Pulm. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1002\/ppul.25733","article-title":"Increasing life expectancy in cystic fibrosis: Advances and challenges","volume":"57","author":"McBennett","year":"2022","journal-title":"Pediatr. Pulmonol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1164\/rccm.202301-0084OC","article-title":"Phase 3 Open-Label Clinical Trial of Elexacaftor\/Tezacaftor\/Ivacaftor in Children Aged 2\u20135 Years with Cystic Fibrosis and at Least One F508del Allele","volume":"208","author":"Goralski","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_6","unstructured":"Lawless, C. (2018). The Impact of Sleep in Children with Cystic Fibrosis. [Ph.D. Thesis, University of Florida]."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/MCP.0b013e32834b6af4","article-title":"The role of exercise in maintaining health in cystic fibrosis","volume":"17","author":"Dwyer","year":"2011","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1586\/ers.12.19","article-title":"Exercise as part of a cystic fibrosis therapeutic routine","volume":"6","author":"Rand","year":"2012","journal-title":"Expert Rev. Respir. Med."},{"key":"ref_9","first-page":"CD002768","article-title":"Physical exercise training for cystic fibrosis","volume":"11","author":"Radtke","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jcf.2013.03.003","article-title":"Effect of supervised training on FEV1 in cystic fibrosis: A randomised controlled trial","volume":"12","author":"Kriemler","year":"2013","journal-title":"J. Cyst. Fibros."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1183\/09031936.00062409","article-title":"Long-term effects of a partially supervised conditioning programme in cystic fibrosis","volume":"35","author":"Hebestreit","year":"2010","journal-title":"Eur. Respir. J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJM199212173272504","article-title":"The prognostic value of exercise testing in patients with cystic fibrosis","volume":"327","author":"Nixon","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1378\/chest.95.2.344","article-title":"The quality of well-being in cystic fibrosis","volume":"95","author":"Orenstein","year":"1989","journal-title":"Chest"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ccm.2014.06.005","article-title":"Cystic fibrosis and sleep","volume":"35","author":"Katz","year":"2014","journal-title":"Clin. Chest Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.smrv.2018.07.002","article-title":"Sleep disturbances and their impact in pediatric cystic fibrosis","volume":"42","author":"Shakkottai","year":"2018","journal-title":"Sleep Med. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Chiu, M., Bartley, B., Gootkind, E., Batool-Anwar, S., Keamy, D.G., Kinane, T.B., Yonker, L.M., and Gipson, K.S. (2025). Evaluating Obstructive Sleep Apnea Utilizing Arterial Tonometry in Individuals with Cystic Fibrosis. Adv. Respir. Med., 93.","DOI":"10.3390\/arm93030020"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/alr.23555","article-title":"Elexacaftor-Tezacaftor-Ivacaftor Improves Sinonasal Outcomes in Young Children With Cystic Fibrosis","volume":"15","author":"Stapleton","year":"2025","journal-title":"Int. Forum Allergy Rhinol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1007\/s00405-023-07859-4","article-title":"Effects of CFTR-modulator triple therapy on sinonasal symptoms in children and adults with cystic fibrosis","volume":"280","author":"Bode","year":"2023","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(24)01134-6","article-title":"Behavioural and sleep issues after initiation of elexacaftor-tezacaftor-ivacaftor in preschool-age children with cystic fibrosis","volume":"404","author":"Benaboud","year":"2024","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1002\/ppul.27100","article-title":"Mental health, sleep, and respiratory health after initiating elexacaftor\/tezacaftor\/ivacaftor treatment in children with cystic fibrosis","volume":"59","author":"Pham","year":"2024","journal-title":"Pediatr. Pulmonol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jcf.2023.05.005","article-title":"Characterization of sleep in emerging adults with cystic fibrosis on elexacaftor\/tezacaftor\/ivacaftor","volume":"23","author":"Meltzer","year":"2024","journal-title":"J. Cyst. Fibros."},{"key":"ref_22","first-page":"170","article-title":"Barriers to Sports Participation and Strategies of Barrier Management","volume":"18","author":"Fuchs","year":"2010","journal-title":"Z. Gesundheitspsychol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1026\/0943-8149\/a000137","article-title":"Measuring Physical Activity and Sports Participation Using the BSA Questionnaire","volume":"23","author":"Fuchs","year":"2015","journal-title":"Z. Gesundheitspsychol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"110316","DOI":"10.1016\/j.jpsychores.2020.110316","article-title":"Assessment of health-related quality-of-life in patients with chronic Rhinosinusitis\u2014Validation of the German Sino-Nasal Outcome Test-22 (German-SNOT-22)","volume":"140","author":"Riedl","year":"2021","journal-title":"J. Psychosom. Res."},{"key":"ref_25","unstructured":"Baur, N., and Blasius, J. (2019). Qualitative Content Analysis. Handbook Methods of Empirical Social Sciences 1, Springer."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e71325","DOI":"10.1002\/ppul.71325","article-title":"Objectively Monitored Sleep in School-Age Children With Cystic Fibrosis and Their Parents","volume":"60","author":"Fidler","year":"2025","journal-title":"Pediatr. Pulmonol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jcf.2022.11.002","article-title":"Steps Ahead: Optimising physical activity in adults with cystic fibrosis: A pilot randomised trial using wearable technology, goal setting and text message feedback","volume":"22","author":"Curran","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Gruber, W., Stehling, F., Blosch, C., Dillenhoefer, S., Olivier, M., Brinkmann, F., Koerner-Rettberg, C., Sutharsan, S., Mellies, U., and Taube, C. (2024). Longitudinal changes in habitual physical activity in adult people with cystic fibrosis in the presence or absence of treatment with elexacaftor\/tezacaftor\/ivacaftor. Front. Sports Act. Living, 6.","DOI":"10.3389\/fspor.2024.1284878"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1123\/pes.22.1.81","article-title":"Seasonal variation in physical activity among children and adolescents: A review","volume":"22","author":"Carson","year":"2010","journal-title":"Pediatr. Exerc. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1123\/jpah.2025-0316","article-title":"Accelerometer-Measured Physical Activity in UK Early Childhood Education and Care Settings: A Cross-Sectional Study","volume":"23","author":"Maishman","year":"2026","journal-title":"J. Phys. Act. Health"},{"key":"ref_31","unstructured":"World Health Organization (2026, March 31). Physical Activity. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/physical-activity."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.sleep.2010.11.011","article-title":"Normative values of polysomnographic parameters in childhood and adolescence: Quantitative sleep parameters","volume":"12","author":"Scholle","year":"2011","journal-title":"Sleep Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e27493","DOI":"10.1002\/ppul.27493","article-title":"Effects of Elexacaftor-Tezacaftor-Ivacaftor on Nasal and Sinus Symptoms in Children With Cystic Fibrosis","volume":"60","author":"Petit","year":"2025","journal-title":"Pediatr. Pulmonol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jcf.2024.01.004","article-title":"Elexacaftor\/tezacaftor\/ivacaftor improves chronic rhinosinusitis detected by magnetic resonance imaging in children with cystic fibrosis on long-term therapy with lumacaftor\/ivacaftor","volume":"23","author":"Wucherpfennig","year":"2024","journal-title":"J. Cyst. Fibros."}],"container-title":["Advances in Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2543-6031\/94\/3\/36\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T18:07:53Z","timestamp":1780682873000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2543-6031\/94\/3\/36"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["arm94030036"],"URL":"https:\/\/doi.org\/10.3390\/arm94030036","relation":{},"ISSN":["2543-6031"],"issn-type":[{"value":"2543-6031","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]}}}